Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-032312
Date:2021-05-11
Issuer: TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

ASELAGE STEVE
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-05-11 S 2,146 d $19.58 186,794 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. this sale is mandated by the issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the issuer. this sale does not represent a discretionary trade by the reporting person.

Elevate your investments